An expert in the preclinical and clinical development of innovative therapies, Dominique Bridon has spent most of his career in North America where he was successively CEO of Biodesy (now BlueLight Therapeutic), a Bay Area start-up backed by 5AM, Roche and Pfizer Ventures revolutionizing the analysis of therapeutic proteins, CTO of EpiVax Oncology, a pioneer in personalized peptide vaccines, and Head of Development for Concarlo, a New York-based company developing cyclin-dependent kinase inhibitors for oncology. He co-founded Conjuchem (IPO on the TSX and acquired by Abraxis). He previously held various management positions at Optivia (acquired by BioIVT), Ipsen, Abbott, Enobia (acquired by Alexion) and Neuronax and served on the scientific boards of Syntaxin (acquired by Ipsen) and Biosortia.
Dominique holds a Master's degree in chemical engineering from the École Nationale Supérieure de Chimie (Paris France). He completed his Ph.D. in organic chemistry at the Paris XI University under the direction of Nobel Prize winner Derek Barton and his postdoctoral fellowship at the University of California, Berkeley.